Abstract
Type I and type II classes of interferons (IFNs) signal through the JAK/STAT1 pathway and are known to be important in adaptive and innate immune responses and in protection against tumors. Although STAT1 is widely considered a tumor suppressor, it remains unclear, however, if this function occurs in tumor cells (cell autonomous) or if STAT1 acts primarily through immune cells. Here, the question of whether STAT1 has a cell autonomous role in mammary tumor formation was addressed in a mouse model of ERBB2/neu-induced breast cancer in the absence and presence of STAT1. For this purpose, mice that carry floxed Stat1 alleles, which permit cell-specific removal of STAT1, were generated. To induce tumors only in mammary cells lacking STAT1, Stat1 floxed mice were crossed with transgenic mice that express cre recombinase and the neu oncogene under the mouse mammary tumor virus LTR (Stat1fl/fl NIC). Stat1 was effectively deleted in mammary epithelium of virgin Stat1fl/fl NIC females. Time-to-tumor onset was significantly shorter in Stat1fl/fl NIC females than in WT NIC (Wilcoxon rank sum test, P = .02). The median time-to-tumor onset in the Stat1fl/fl NIC mice was 49.4 weeks, whereas it was 62.4 weeks in the WT NIC mice. These results suggest that STAT1 in mammary epithelial cells may play a role in suppressing tumorigenesis. The Stat1 floxed allele described in this study is also a unique resource to determine the cellular targets of IFNs and STAT1 action, which should aid our understanding and appreciation of these pathways.
MeSH Terms
Animals
Blotting, Western
Cell Nucleus/metabolism
Cells, Cultured
Embryo, Mammalian/cytology
Epithelium/metabolism
Female
Fibroblasts/metabolism
Kaplan-Meier Estimate
Male
Mammary Glands, Animal/metabolism
Mammary Neoplasms, Animal/genetics,metabolism,pathology
Mice
Mice, 129 Strain
Mice, Knockout
Mice, Transgenic
Receptor, ErbB-2/genetics,metabolism
STAT1 Transcription Factor/genetics,metabolism
Tumor Burden
Tumor Cells, Cultured
Chemicals
STAT1 Transcription Factor
Stat1 protein, mouse
Receptor, ErbB-2
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Klover Peter J
Laboratory of Genetics and Physiology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. peter_klover@yahoo.com
Muller William J
Robinson Gertraud W
Pfeiffer Ruth M
Yamaji Daisuke
Hennighausen Lothar
References (20)
20 references, click to expand
-
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61
PMID: 9636188
-
Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.
Nat Rev Clin Oncol. 2009 Aug;6(8):478-87
PMID: 19546865
-
An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer.
Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18490-5
PMID: 19001271
-
Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease.
PLoS Genet. 2006 Aug 18;2(8):e131
PMID: 16934001
-
Links between innate and adaptive immunity via type I interferon.
Curr Opin Immunol. 2002 Aug;14(4):432-6
PMID: 12088676
-
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway.
Cell. 1996 Feb 9;84(3):431-42
PMID: 8608597
-
Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation.
Science. 2001 Jul 13;293(5528):300-3
PMID: 11452125
-
Insights from transgenic mouse models of ERBB2-induced breast cancer.
Nat Rev Cancer. 2007 May;7(5):389-97
PMID: 17446858
-
Osteopontin regulates ubiquitin-dependent degradation of Stat1 in murine mammary epithelial tumor cells.
Neoplasia. 2007 Sep;9(9):699-706
PMID: 17898865
-
Next generation of immunotherapy for melanoma.
J Clin Oncol. 2008 Jul 10;26(20):3445-55
PMID: 18612161
-
Effects of systemic interferon-alpha (IFN-alpha) on the antigenic phenotype of melanoma metastases. EORTC melanoma group cooperative study No. 18852.
Melanoma Res. 1993 Jun;3(3):173-80
PMID: 8104570
-
ShcA signalling is essential for tumour progression in mouse models of human breast cancer.
EMBO J. 2008 Mar 19;27(6):910-20
PMID: 18273058
-
Type I interferon receptors: biochemistry and biological functions.
J Biol Chem. 2007 Jul 13;282(28):20053-7
PMID: 17502368
-
Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease.
Cell. 1996 Feb 9;84(3):443-50
PMID: 8608598
-
Cancer immunoediting: from immunosurveillance to tumor escape.
Nat Immunol. 2002 Nov;3(11):991-8
PMID: 12407406
-
STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells.
Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1714-9
PMID: 14755057
-
First-line therapy for chronic myeloid leukemia: Past, present, and future.
Am J Hematol. 2009 May;84(5):287-93
PMID: 19306355
-
Cre-mediated gene deletion in the mammary gland.
Nucleic Acids Res. 1997 Nov 1;25(21):4323-30
PMID: 9336464
-
STAT1 acts as a tumor promoter for leukemia development.
Cancer Cell. 2006 Jul;10(1):77-87
PMID: 16843267
-
The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.
J Clin Invest. 2003 Jul;112(2):170-80
PMID: 12865406